Skip to content
Clinical Trials – home

Lietuvos sveikatos mokslu universiteto Kauno ligonine

Verified siteinfo

Lithuania A. Krisciuno G. 2, Kauno R. Sav., 53137 Kaunas, Lithuania

  • 2 trials recruiting
  • Major depression · Schizophrenia
  • Adult patients

About Specializations

Lietuvos sveikatos mokslu universiteto Kauno ligonine in Kaunas, Lithuania specialises in clinical trials of conditions such as Major depression, Schizophrenia, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology – Mental Disorders

The Lithuanian University of Health Sciences Kaunas Hospital is conducting focused research in psychiatry and psychology. One focus is Major Depressive Disorder. Another focus is Schizophrenia. Current studies evaluate new adjunctive compounds, assess long‑term safety, and aim to improve symptom relief.

  • Adjunctive therapy evaluation
  • Long‑term safety monitoring
  • Cognitive impairment in schizophrenia
  • Genotype‑guided depression treatment

The program includes four active studies led by three investigators, contributing valuable data on novel agents and personalized approaches for mental health care in Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
A. Krisciuno G. 2, Kauno R. Sav.53137 KaunasLithuania
Recruiting now
2 trials
Conditions studied
2
Partner status
Verified site

More sites in KaunasLithuania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Iclepertin
  • Sponsor:Boehringer Ingelheim International GmbH

Major depression

Not recruiting

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Nelivaptan
  • Sponsor:HMNC Holding GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.